Products Categories
  • Ms.ye
    Tel: +86 755 26588093

  • Mobile:
  • Tel:+86 755 26588093
  • Fax:+86 755 26588022
  • URL:http://www.hybio.com.cn
  • Province/state:guangdong
  • City:Shenzhen
  • Street:No.9 Linkong West Street, Hengdian Street, Huangpi District, Wuhan City, China.
  • MaxCard:
Home > Products >  Bivalirudin Peptides for Bleeding Reduction

Bivalirudin Peptides for Bleeding Reduction CAS NO.128270-60-0

  • Min.Order: 1 Gram
  • Payment Terms: L/C,T/T
  • Product Details

Keywords

  • Bivalirudina
  • Bivalirudine
  • Bivalirudin

Quick Details

  • ProName: Bivalirudin Peptides for Bleeding Redu...
  • CasNo: 128270-60-0
  • Molecular Formula: C98H138N24O33
  • Appearance: white to off white
  • Application: Bivalirudin is a kind of synthetic nov...
  • DeliveryTime: Ready in Stock
  • PackAge: Aluminum Foil Bag
  • Port: HK/Shenzhen
  • ProductionCapacity: 500 Kilogram/Year
  • Purity: ≥98%
  • Storage: 2-8 degree
  • Transportation: Cold chain and cool storage delivery f...
  • LimitNum: 1 Gram

Superiority

The first listed company in peptides industry, mature process, stable and advaced technology,API capacity reaches to 500kg with 3 main factory sites.

Details

Application


Bivalirudin has a inhibitory effect on soluble and thrombus-bound thrombin in vitro. That effect cannot be affected by products that are released by platelet, and it can extend plasma activated partial thromboplastin time, thrombin time and prothrombin time of normal human with a dose-dependent manner. It is suitable for percutaneous coronary intervention (PCI) unstable angina. In 2010, domestic PCI operation cases reached 300,000. The annual compound growth rate was over 30%. This showed that sales prospects of bivalirudin after the listing are considerable.


Clinically experiments prove that bivalirudin is more effective than the current mainstream unfractionated heparin/low molecular weight heparin and platelet glycoprotein receptor antagonist in applications around PCI.

Especially the risk of bleeding has a significant reduction, and the use safety of anticoagulants is greatly improved: 


1. It can significantly reduce the incidence of bleeding in elective PCI patients. The total clinical outcome risk fell 14%.
2. It does not cause antibody-mediated thrombocytopenia.
3. Reversibly bind with thrombin. Short half-life. Hard to develop ischemic and hemorrhagic complications. 
4. It is not mainly excreted through the kidneys and can be safely used in patients with renal impairment. 

 

FAQ

Q1. Are you a trade company or manufactures

A: We are an GMP approved manufacturer specialized in peptides API products, OEM is available, Key products have obtained USDMF and EDMF. Production lines passed US and EU Authorities audit.

Q2. What is your MOQ

A: We support trial order, 1g is min. 

Q3. What is your delivery date

A: Can be shipped within 2days after payment.

Q4. What is your payment term

A: T/T, LC.

Q5. Which country is your products sold

A: Our products sold worldwide expecially to Europe, North America, South America and Africa.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog